常山藥業(300255.SZ)上半年淨利1.23億元同比增16.20%
格隆匯8月14日丨常山藥業(300255.SZ)披露2019年半年度報告，報告期內公司實現營業收入9.03億元，同比增長26.29%；歸屬於上市公司股東的淨利潤1.23億元，同比增長16.20%；經營活動現金淨流出2.42億元，而上年同期為淨流入802.41萬元；基本每股收益0.13元。
報告期末，公司總資產38.71億元，較上年度末38.45億元增長0.68%；歸屬於上市公司股東的淨資產26.36億元，較上年度末25.13億元增長4.90%。
完善產業鏈佈局：近年來，受國家產業政策影響，隨着上游肝素粗品落後產能的逐步淘汰，肝素粗品價格持續上漲。為應對行業變化趨勢，公司在加大肝素粗品儲備的同時，建設自營肝素粗品加工基地。2019年上半年，專業化運營肝素粗品生產的凱庫得公司實現投產運營。由於投產時間較短，2019年上半年，凱庫得僅實現營業收入423.54萬元，未來隨着產量提升，將對公司原料供應產生重大影響。
主要產品銷售方面：報告期內，公司繼續加強營銷團隊建設，積極進行渠道優化和市場推廣，做好各地招投標工作。2019年上半年低分子肝素製劑實現收入6.05億元，較上年同期增長22.38%，主要是低分子肝素製劑銷量較上年同期增加導致。在原料藥銷售方面，受非洲豬瘟疫情和生豬出欄量降低的影響，普通肝素原料藥和低分子肝素原料藥的銷售價格同比增長，普通肝素原料藥實現收入2.04億元，較上年同期增長39.51%；低分子肝素原料藥實現收入7904.44萬元，較上年同期增長22.20%。
藥品研發申報及註冊認證情況：報告期內，公司收到國家藥品監督管理局核准簽發的關於依諾肝素鈉注射液的藥品註冊批件，依諾肝素鈉注射液功能主治：預防深靜脈血栓形成及肺栓塞；治療已形成的靜脈血栓；預防血液透析時體外循環中血栓的形成；治療不穩定性心絞痛和非Q波心梗。該藥品註冊批件的獲得豐富了公司核心產品種類。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
